RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Ruijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07797218, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 70 years; sex: women only

    Registered eligibility fields

  2. Histologically confirmed invasive breast cancer, with primary tumor diameter ≥ 2.0 cm, Stage II-III as assessed by local standard methods.

    Inclusion criterion 4

  3. For non-menopausal (amenorrhea < 12 months) or non-surgically sterile female patients (without ovaries and/or uterus): Agreement to abstain or use reliable and effective contraception during treatment and for at least 6 months after the last dose of study treatment.

    Inclusion criterion 9

    Currently enrolled in or previously participated in a study of an investigational drug and received investigational treatment or used an investigational device within 4 weeks before the first dose of study treatment (12 months for investigational drugs/devices with anti-cancer or anti-proliferative properties).

    Exclusion criterion 16

  4. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1.

    Inclusion criterion 6

  5. Other malignancies within the past 5 years, except cured carcinoma in situ of the cervix or non-melanoma skin cancer.

    Exclusion criterion 9

    Known history of Human Immunodeficiency Virus (HIV) infection.

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07797218, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed informed consent.
  • Age: Female patients aged 18-70 years.
  • Breast cancer meeting the following criteria:
  • Histologically confirmed invasive breast cancer, with primary tumor diameter ≥ 2.0 cm, Stage II-III as assessed by local standard methods.
  • HER2-positive breast cancer, defined as Immunohistochemistry (IHC) score 3+ or In Situ Hybridization (ISH) showing HER2 gene amplification.
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1.
  • All required baseline laboratory tests and imaging studies completed before randomization.
  • Adequate organ function
  • For non-menopausal (amenorrhea < 12 months) or non-surgically sterile female patients (without ovaries and/or uterus): Agreement to abstain or use reliable and effective contraception during treatment and for at least 6 months after the last dose of study treatment.
  • Investigator judgment that the patient can comply with the study protocol.

Exclusion Criteria:

  • Bilateral breast cancer or metastatic (Stage IV) breast cancer.
  • Significant cardiac disease:
  • History of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass within the past 6 months.
  • New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF) or history of NYHA Class III or IV CHF.
  • High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate > 100 bpm, significant ventricular arrhythmias (e.g., ventricular tachycardia), or higher-grade atrioventricular (AV) block.
  • Angina requiring anti-anginal medication.
  • Clinically significant valvular heart disease.
  • ECG evidence of transmural myocardial infarction.
  • Other malignancies within the past 5 years, except cured carcinoma in situ of the cervix or non-melanoma skin cancer.
  • Severe systemic infection or patients with other serious diseases.
  • Major non-breast surgery within 4 weeks of randomization, or patients who have not fully recovered from such surgery.
  • Known history of Human Immunodeficiency Virus (HIV) infection.
  • Active hepatitis B or hepatitis C virus infection.
  • Known allergy or intolerance to the study drugs or their excipients.
  • Prior cytotoxic chemotherapy, endocrine therapy, biological therapy, or radiotherapy for any reason.
  • Currently enrolled in or previously participated in a study of an investigational drug and received investigational treatment or used an investigational device within 4 weeks before the first dose of study treatment (12 months for investigational drugs/devices with anti-cancer or anti-proliferative properties).
  • Vaccination with a live vaccine within 30 days before the first dose of the investigational drug.
  • Psychiatric illness or substance abuse history that could affect compliance with trial requirements.
  • Pregnancy or breastfeeding, or female patients of childbearing potential who refuse to take appropriate contraceptive measures during the trial.
  • Patients judged by the investigator to be unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07797218, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07797218, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07797218